Chen Jing

Associate Professor, PhD

Research Interests: Pharmaceutical Policy and Law, Pharmacy Administration,Regulatory Science

Tel: +86-010-82805879

Email:jingchen@bjmu.edu.cn

EDUCATION

Doctor of Philosophy, Peking University

Master of Science, China Pharmaceutical University

Bachelor of Science, China Pharmaceutical University

ACADEMIC APPOINTMENTS

2003- present    Peking University, School of Pharmaceutical Sciences, Department of Pharmacy Administration and Clinical Pharmacy

Associate Professor, Lecturer ,Assistant Lecturer / Teaching Assistant

PROFESSIONAL AFFILIATIONS

Member, Professional Committee of Pharmaceutical Intellectual Property, Chinese Pharmaceutical Association

Member, Professional Committee of Drug Regulation and Policy, China Society for Drug Regulation

Member, Professional Committee of Regulatory Science and Pharmacoeconomics, Beijing Pharmaceutical Association

RESEARCH PROJECTS

1. National Natural Science Foundation of China (NSFC) : Research on Pharmaceutical Intellectual Property Protection and Its Impact on Drug Pricing in China.

2. National Natural Science Foundation of China (NSFC): Factors Influencing Physician Prescribing Behavior and Quasi-Experimental Intervention Research from the Perspective of Generic vs. Brand-name Drug Selection.

3. National Major Scientific and Technological Special Project for "Significant New Drugs Development": Regulatory System Construction for Pediatric Drug Varieties and Key Technology R&D.

4. Major Project on Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases: Research on the Mechanism of Technological Innovation Supporting the High-Quality Development of the Drug Supply Guarantee System.

5. Capital High-End Think Tank Project: Research on the High-Quality Development of the Innovative Drug Industry in Beijing.

6. Chinese Academy of Sciences (CAS) Science and Technology Think Tank Project: Problems and Countermeasure Recommendations for the Development of Innovative Drugs in China.

7. National Health Commission (NHC): Research on Supporting the Development of Innovative Drugs Across the Entire Chain.

8. National Medical Products Administration (NMPA): Research on Management Issues in the Review and Approval of Radiopharmaceuticals.

9. NMPA: Research on the Revision of the Administrative Measures for Medical Toxic Drugs.

10. NMPA: Phase-specific Evaluation of the Reform Results of the "Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices."

11. Beijing Drug Administration: White Paper on Food and Drug Safety Status in Beijing.

12. NMPA: Research on China’s Pharmaceutical Data Protection System.

13. Ministry of Finance & UNICEF: Research on Drug Pricing Systems Amidst Deepening Healthcare Reform.

14. China National Intellectual Property Administration (CNIPA): Investigation and Research on Typical Cases of Pharmaceutical Intellectual Property.

15. China Price Association: Research on the Prices of Patented Drugs in China.

REPRESENTATIVE PUBLICATIONS

1. Wang, Zhiyuan , Chen jinget al. "Influencing Factors of Generic Prescribing Behavior of Physicians: A Structural Equation Model Based on the Theory of Planned Behavior." Risk Management and Healthcare Policy 17.2024(2024):1375-1385.

2. Wang R , Wang Z , Li X ,et al.Chinese Physicians' Preference for Prescribing Brand-Name vs. Generic: A Discrete Choice Experimen[J].INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2024, 13(1)

3. Li W, Li X, He Y, et al. Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market[J]. PharmacoEconomics-Open, 2025: 1-10.

4. Li W, Chen J, Shi L. Advancing pediatric drug development in China: implementation of the national priority R&D encouragement list[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(3): 260.

5. Huang J, Yao Z, Chen J, et al. (2025). Retrospective analysis of clinical trial development trends of innovative drugs in China from 2020 to the first half of 2025. Herald of Medicine, 1-10. [Online First, 2026-01-15].

6. Li W, Han S, Chen J, et al. (2025). Practice of European Joint Clinical Assessment (JCA) and its enlightenment to China. Progress in Pharmaceutical Sciences, 49(05): 330-336.

7. Wang Z, He Y, Chen J, et al. (2022). Research on the implementation effect of foreign policies promoting the use of generic drugs. Chinese Journal of New Drugs, 31(22): 2185-2192.

8. Wang Z, Han T, Chen J, et al. (2023). Research on the prices of pediatric essential medicines in 18 tertiary specialized children's hospitals. Chinese Journal of Hospital Pharmacy, 43(09): 953-957.

9. Wang Z, Han T, Chen J, et al. (2022). Research on the accessibility of pediatric essential medicines in 18 tertiary specialized children's hospitals in China. China Pharmacy, 33(18): 2177-2181.

10. Bai L, Zhang Y, Chen J, et al. (2021). Impact of patent expiration on drug prices and market share. Chinese Journal of New Drugs, 30(06): 481-488.

11. Bai L, Fan P, Chen J, et al. (2021). Trends in new drug R&D and approval based on US new drug approvals from 1985 to 2019. Chinese Journal of New Drugs, 30(20): 1830-1835.

12. Wu H, Li X, Chen J, et al. (2021). Impact of Volume-Based Procurement (VBP) policy on the clinical use of originator and generic drugs in 5 public hospitals in Northern Jiangsu. Pharmaceutical and Clinical Research, 29(03): 237-240.

13. Wang M, Fan P, Chen J, et al. (2021). Analysis of orphan drug designation and marketing approval in the United States. Chinese Pharmaceutical Affairs, 35(12): 1406-1413.

14. Han T, Wang R, Chen J, et al. (2021). Analysis of the usage of the 7th WHO Model List of Essential Medicines for Children in children's hospitals. Chinese Journal of Hospital Pharmacy, 41(09): 869-874+885.

15. Chen J, Fan P, Han S, et al. (2021). Analysis of generic drug policies in China. World Clinical Drugs, 42(01): 16-20.